Mirum Pharmaceuticals Enters into Definitive Agreement to Acquire Bluejay Therapeutics, Expanding Global Leadership in Rare Disease
Mirum Pharmaceuticals, Inc. - common stock (MIRM)
Last mirum pharmaceuticals, inc. - common stock earnings: 3/12 04:02 pm
Check Earnings Report
Company Research
Source: Business Wire
-Planned acquisition of brelovitug for chronic hepatitis delta virus (HDV) with Breakthrough Therapy and PRIME designations-Anticipated to be highly synergistic with Mirum’s liver expertise and proven global commercial capabilities-HDV: Large, high unmet-need rare liver disease with no FDA-approved therapies-Top-line Phase 3 results expected in 2H 2026-Conference call today, December 8, 2025 at 8:30 am ET/5:30 am PT FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leading rare disease company, today announced its entry into a definitive agreement to acquire Bluejay Therapeutics, a privately held biotechnology company focused on viral and liver diseases. The transaction would add worldwide rights to brelovitug, a late-stage, fully human monoclonal antibody with Breakthrough Therapy and PRIME designations for chronic hepatitis delta virus (HDV) to Mirum’s portfolio of rare liver programs. This acquisition is expected to advance Mirum’s leadership in
Show less
Read more
Impact Snapshot
Event Time:
MIRM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MIRM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MIRM alerts
High impacting Mirum Pharmaceuticals, Inc. - common stock news events
Weekly update
A roundup of the hottest topics
MIRM
News
- Mirum Pharmaceuticals (NASDAQ:MIRM) had its "strong-buy" rating reaffirmed by analysts at Raymond James Financial, Inc..MarketBeat
- Mirum Pharmaceuticals (MIRM): Assessing Valuation After Strong Long-Term Returns and Recent Share Price Pullback [Yahoo! Finance]Yahoo! Finance
- Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business Wire
- Mirum Pharmaceuticals (NASDAQ:MIRM) had its "outperform" rating reaffirmed by analysts at Leerink Partners.MarketBeat
- Mirum Pharmaceuticals (NASDAQ:MIRM) was given a new $100.00 price target on by analysts at Leerink Partners.MarketBeat
MIRM
Earnings
- 11/4/25 - Beat
MIRM
Sec Filings
- 12/8/25 - Form 8-K
- 12/5/25 - Form SCHEDULE
- 12/2/25 - Form 4
- MIRM's page on the SEC website